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Sickle cell Disease (SCD) is an autosomal recessive disorder that affects 50,000 to 100,000 
people in the United States. This disorder is characterized by pain episodes, acute chest 
syndrome, splenic sequestration, infection, stroke, aplastic crisis, and priapism. Hydroxyurea 
(HU) is a drug that is clinically effective in reducing pain episodes, hospitalizations, and total 
health care costs. However, studies show that HU continues to be underutilized in individuals 
with SCD.  There is evidence to suggest poor adherence to HU among people in this population 
and studies have identified a number of barriers at the patient, caregiver, provider and system 
wide levels. Issues with adherence strongly impacts Health Related Quality of Life (HRQOL) of 
individuals with SCD, making it a public health concern. While there are reports available in the 
literature on the qualitative analyses of barriers experienced by this population, there have been 
no known studies that have examined patient reported treatment satisfaction. Our hypothesis is 
that barriers to adherence of HU and treatment satisfaction play a significant role in medication 
adherence. 
The objective is three-fold: 
1. To determine the barriers to adherence of hydroxyurea for individuals with SCD 
2. To determine the treatment satisfaction of hydroxyurea in individuals with SCD 
3. To determine any correlation between the treatment satisfaction and the barriers to HU 
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The participants in this study include individuals who have been on HU for at least 6 
months. Pediatric, caregiver and adult participants were recruited from the University of 
Pittsburgh Medical Center and Children’s Healthcare of Atlanta. Only adult participants were 
recruited from Children’s National Medical Center, Washington DC. The information was 
collected using two surveys administered to all individuals. The TSQM-9 (Treatment 
Satisfaction Questionnaire for Medication) was used to evaluate Hydroxyurea treatment 
satisfaction in patients. The Adherence Starts with Knowledge (ASK-12) survey along with the 
additional barriers survey were used to evaluate the barriers to adherence of Hydroxyurea. All 
surveys were modified for caregiver responses in the pediatric settings. The surveys were 
administered over a period of one year. 
 The results of this study revealed low levels of barriers and moderately high levels of 
treatment satisfaction. The survey results indicate that two specific questions present in the 
additional barriers surveys may be examined in greater detail. Weak linear correlation was 
observed between several categories of barrier surveys and the subsets of the treatment 
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1.0  INTRODUCTION 
Sickle cell disease (SCD) is an inherited blood disorder that affects 50,000 to 100,000 people in 
the United States and over 250 million people worldwide. It is a chronic disabling disorder that 
can decreases one’s life expectancy by 25-30 years.1 This disorder is clinically characterized by 
vaso-occlusive episodes and hemolysis. Individuals with SCD are often hospitalized for acute 
complications such as painful episodes, acute chest syndrome, splenic sequestration, infection, 
stroke, aplastic crisis and priapism. 2 Treatment and management of complications related to 
SCD involves home remediation or treatment in the Emergency Department (ED). This 
condition has a negative impact on the quality of life for children, adolescents and adults who are 
affected.  2; 3 
In the United States, it is mandatory that all newborns be screened for 
hemoglobinopathies (including SCD) in order to start prophylactic treatment and anticipatory 
guidance. Hydroxyurea (HU) was approved in 1996 for treatment of symptoms in individuals 
with sickle cell anemia.1; 4 HU is a myelo-suppresive agent that raises the levels of fetal 
hemoglobin in the bloodstream. This effectively decreases the rate of vaso-occlusive and acute 
chest syndrome episodes by 50%. 5 Clinical studies show that individuals regularly using HU 
over a period of time show reduced mortality, lower hospitalizations, and lower medical costs 
among people with SCD.6; 7 HU is currently administered as an oral daily drug. 4   
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Although HU has been established as an important therapeutic agent, there is evidence to 
support that it is underutilized in individuals with SCD. Adherence to HU has been determined to 
be a very important concern for individuals being treated. Physician reports claim that two thirds 
of their patient population has concerns with adherence.8 In two large clinical studies involving 
pediatric patients, 10% to 20% of participants stopped taking HU because of non-adherence. 
Non-adherence is also expected to be higher outside of a clinical trial. 9 
Barriers to adherence of HU have been identified at the patient, provider and system level 
and are described in the National Institutes of Health (NIH) Consensus Development 
Conference. At the patient level, barriers that have previously been outlined include lack of 
access, lack of knowledge, fear of side effects, concerns for male infertility, cost of medication, 
patient compliance with blood tests and taking medication.10 Other barriers that have been 
determined include frequent monitoring, unavailability in pharmacies and time taken for benefits 
to become apparent. 1; 9 There is limited research that has assessed patient perceived treatment 
satisfaction to HU as a medication.  
This project recognizes the need to identify patient reported barriers to the use of 
hydroxyurea and understand patient reported treatment satisfaction of HU. It aims to determine 
hydroxyurea specific barriers for sickle cell disease, as well as patient perceived treatment 
satisfaction for this drug and to check for any correlation between HU specific barriers and 
patient reported treatment satisfaction. One hundred and forty nine individuals from three 
different locations participated in this study by completing qualitative surveys for treatment 
satisfaction and barriers to Hydroxyurea adherence. The surveys were administered over a period 
of one year.  
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2.0  BACKGROUND AND SIGNIFICANCE 
2.1 SICKLE CELL DISEASE 
Every year, around 2000 babies are born in the United States with sickle cell disease (SCD). 
SCD is both a chronic and a lifelong condition and has often been associated with a decreased 
lifespan. 1 This condition is most common in individuals of African, South or Central American, 
Caribbean, Mediterranean, Indian and Saudi Arabian ancestry. 1 
SCD is a genetic blood disorder of hemoglobin that damages and deforms the red blood 
cells (RBCs) or erythrocytes. In individuals with SCD, the red blood cells become deoxygenated, 
dehydrated, and crescent shaped. The sickle shaped RBCs sometimes break down and causes 
anemia. These cells tend to form aggregates or stick to the walls of the blood vessels. This blocks 
the blood flow in limbs or organs that causes the painful episodes characteristic of this condition. 
These episodes can cause damage to the eyes, brain, heart, lungs, kidney, liver, bones, and 







2.2 IMPACT ON INDIVIDUAL AND SOCIETY 
2.2.1 Clinical presentation  
Clinical manifestations vary with the genotype of SCD. Signs and symptoms of this condition 
can manifest in individuals by 5-6 months of age and continue throughout their life. Fetuses and 
new born children produce a high level of fetal hemoglobin (different from adult hemoglobin) 
and it helps them to be relatively free of the manifestations of SCD. 12 SCD can show variable 
presentation ranging from asymptomatic individuals to episodic pain events referred to as 
“crisis” events. Persistent pain is a complex phenomenon of SCD.11 This condition can impact a 
variety of organ systems and cause multiple different disease-related complications. 2  
Individuals with SCD are frequently seen in Emergency Departments and hospitals for their pain 
episodes.  
Symptoms associated with Sickle cell disease: 
Pain is seen in the form of vaso-occlusive episodes and can be observed in individuals as 
young as 6 months of age. 2; 12 Vasocclusion is an unpredictable ischemic event that occurs when 
the sickled RBCs block blood vessels.  They can be frequent, severe and last from a few hours to 
weeks. 11; 13 
Some of the complications associated with SCD include Acute Chest Syndrome (ACS), 
aplastic crisis, acute vaso-occlusive pain, priapism in males, stroke, leg ulcers, splenic 
sequestration, susceptibility to serious infections, transfusion related iron overload, retinopathy, 
avuncular necrosis of the hip and shoulders, hemolytic anemia, chronic damage to the lungs, 
bones and kidneys.1; 3; 9; 14; 15 
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Organ damage often results in other long term disease related outcomes such as delayed 
puberty and decreased lung function.11 Infections and lung disease are the leading causes of 
death in people with SCD. 1 
 Sickle cell crisis can be caused by dehydration, exposure to cold, infection and 
environments with low oxygen tension. Pain episodes can be acute, chronic or both and are 
unpredictable and recurrent.  11 
2.2.2 Health Related Quality of Life (HRQOL)  
The World Health Organization (WHO) defines health as being not only the absence of disease 
and infirmity but also the presence of physical, mental and social well-being. Health related 
quality of life (HRQOL) refers to the “physical, psychological and social domains of heath seen 
in areas influenced by a person’s experiences, beliefs, expectations and perceptions”. If a person 
has a life closer to the standard of normalcy, he/she is said to have better HRQOL. 2 A 
comparison of HRQOL in children with SCD and matched controls showed significantly lower 
overall HRQOL reported by both the children with SCD and their parents. 2 
The relationship between sickle cell complications leading to decreased health related 
quality of life has been well documented in both adults and youth with SCD. Sickle cell related 
pain events are common manifestations of this condition and are recurrent, acute and 
unpredictable. Studies show that more effective management of persistent pain can lead to 
improved quality of life in adults with SCD. 2 Fuggle and colleagues demonstrated that sickle 
cell pain events are associated with decrements in social and recreational functioning as well as 
school attendance for youths with SCD. 16 It is essential to understand the association of pain 
with HRQOL to improve pain management and other health related outcomes.16 The 
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hospitalizations and school absences could be expected to have a negative impact in the HRQOL 
for children and adolescents with SCD. 2 
2.2.3 Public health implications 
The HRQOL impairments for youth with SCD are associated with personal and healthcare costs 
in pediatric populations.16 Adults living with Sickle cell disease have high rates of 
unemployment. Studies propose that the unemployment may be caused by irregular school 
attendance that could prevent children from acquiring adequate job skills. Studies display weak 
evidence to support direct links between pain severity, SCD symptoms and unemployment. 17 
SCD poses to be an enormous financial burden for individuals, families and even third-
party payers. Studies suggest interventions designed to control pain episodes could help avoid 
hospitalizations and may help reduce personal and economic burden of the disease. 5 Pain 
accounts for around 80% of all hospitalizations for children with SCD. Research shows that pain 
is also often managed at home and therefore goes unreported.  
The public health issues and policies associated with SCD vary widely by country 




2.3 GENETICS AND INHERITANCE 
2.3.1 Molecular genetics and pathophysiology 
Sickle cell disease was the first genetic disease for which a specific molecular defect in a gene 
was identified. It is one of the genetic conditions screened for by the newborn screening program 
in the United States. 1 
Sickle hemoglobin is produced when the sickle mutation is present in the beta globin 
coding gene. This gene is present on chromosome number 11.  It is estimated that close to 2 
million individuals in the United States has one sickle hemoglobin gene and one normal 
hemoglobin gene. They are said to have sickle cell trait.  
Sickle cell disease occurs when an individual inherits the gene for sickle hemoglobin 
from both parents. Individuals who inherit one sickle hemoglobin gene and one abnormal 
hemoglobin gene from the other parent also have sickle cell disease and are said to be 
“compound heterozygotes”.  There are several genotypes that can cause sickle cell disease, 
namely, SS, Sβ0, SC, SD, Sβ+ SOarab1 
SCD is used as a broad term to define a group of autosomal recessive disorders. 12 This 
condition is characterized by the production of abnormal hemoglobin by the inherited sickle 
hemoglobin gene. The genotype of an individual is often seen to have a direct correlation with 
the severity of disease. 12 
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2.4 PREVENTION AND MANAGEMENT 
2.4.1 Prevention 
Preventive approach to genetic conditions involve primary, secondary and tertiary measures. 
Primary preventive strategies involve taking measures to prevent the disease from occurring. 
They include carrier screening and genetic counseling to encourage informed decision making. 
Secondary prevention measures involve early detection and preclinical interventions such as 
newborn screening followed by prophylactic treatment of young children. These measures also 
include education of parents. 
Tertiary prevention measures are developed to minimize the effects of the disease. They 
include hydroxyurea therapy, prophylactic transfusions to prevent stroke recurrence, daily folic 
acid supplementation to prevent megaloblastic anemia, outpatient administration of analgesics 
and hydration for pain control. Efforts to cure sickle cell disease using bone marrow 
transplantation or gene therapy are currently being investigated.12 
2.4.2 Management and treatment 
Treatment of pain episodes involve symptomatic care.10 The current non-specific treatments 
involve penicillin prophylaxis, hydroxyurea, pain medications, blood transfusions and 
vaccines.11 Management of complications related to sickle cell disease may require 
hospitalization or treatment at home, in an ambulatory setting or in the ED. Standard treatments 




Hydroxyurea (HU) was initially synthesized in Germany in the year 1869. Around 50 years ago, 
it was used as an anticancer drug to treat myelo-proliferative syndromes, some types of 
leukemia, melanoma and ovarian cancer. It was also previously used to treat psoriasis.  
The first trial conducted to observe the effects on HU in individuals with SCD was in 
1984. Studies revealed increased production of the fetal hemoglobin-containing erythrocytes and 
diminished number of sickled erythrocytes in circulation for individuals on this medication. A 
HU case-control research study in the 1990s ended early because it clearly showed reduced 
number and severity of pain episodes in individuals on HU compared to those on the placebo.  
In 1995, a randomized controlled trial for adults with SCD called the Multicenter Study 
of Hydroxyurea in Sickle Cell Anemia (MSH trial) found HU significantly reduced the number 
of painful events, ACS and transfusions. A nine year follow up to this study showed that HU was 
associated with reduction in mortality, minimum side effects, and was safe.10 In 1998, the United 
States Food and Drug Administration approved HU for prevention of pain crisis in adults with 
SCD. 1 
HU is a myelo-suppressive agent. This drug helps increase the level of fetal hemoglobin 
present in the blood stream which in turn causes a general increase in the amount of hemoglobin 
in the blood stream that decreases the rate of pain crisis events by 50% in adults. 5 
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2.5.2 Drug action and drug use 
It often takes 3 to 6 months of treatment for the patient to have a clinical response to HU therapy. 
In 2002, NIH published recommendations for HU in children and adults which stated that HU 
therapy should be initialized in individuals with “frequent pain episodes”. Preventive methods 
for pain are limited and HU is the only drug shown to decrease the frequency of SCD associated 
pain events. 10 
2.5.3 Drug Efficacy 
Drug efficacy can be defined as the therapeutic effect of HU in a controlled setting like a clinical 
trial. Response to HU therapy has been seen to vary by haplotype or genotype. HU is the only 
drug available for individuals with SCD that can modify disease process. The evidence for this is 
strongly observed in adults but is limited in children due to the nature of clinical trials in this 
population.1  
2.5.4 Drug effectiveness 
Drug effectiveness is the therapeutic effect of an intervention as seen or observed in patients in 
their usual care setting. Data suggests that specific treatments such as hydroxyurea or stem cell 
therapy (SCT) may improve HRQOL in children and adolescents. Ballas and colleagues (2010) 
used information collected in the multicenter study of HU in sickle cell anemia to report that HU 
improves some aspects of Quality of Life (QOL) in adult patients who have moderate to severe 
sickle cell anemia.2 
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Many studies indicate strong evidence to support HU’s role in reducing frequency of 
hospitalization in children with SCD and moderate evidence to show its role in decreasing the 
frequency of pain events. 5 
An issue faced when determining effectiveness is that precise estimates of the number of 
people with sickle cell disease in the United States and the number of people receiving HU 
treatment is lacking. Another concern that plays a role in determining effectiveness of HU is the 
adherence to medication.  Although data on the effectiveness of HU treatment in individuals with 
SCD is limited, it appears to be highly effective but underutilized. 1 
2.5.5 Cost effective 
The results from a multicenter study of HU in individuals with SCD shows that adult patients 
treated with HU had a 44% decrease in hospitalizations compared to those taking placebo. This 
translated into cost savings for individuals in HU and suggests that HU therapy is cost effective.5 
2.5.6 Short and long term effects  
Leukopenia, thrombocytopenia and anemia are frequent and expected short term effects of HU 
therapy that usually resolve within 1 to 2 weeks. They can be anticipated and prevented by 
discontinuing HU treatment. Skin rash and pneumonitis are infrequently observed short term 
effects of HU therapy. Nausea is infrequently observed with this treatment and there is no 
evidence to suggest that this side effect is related to HU. Temporarily decreased sperm count or 
sperm abnormalities have been observed in this population but have not been sufficiently 
evaluated. 
12 
 Side effects that have been infrequently associated with HU use include skin and nail 
darkening. There is insufficient or low evidence to support the association of increased risk for 
superficial skin cancer and permanently decreased sperm count with this treatment.  
HU when taken during pregnancy can increase risk for miscarriage, birth defects, 
restricted fetal growth or postnatal development. There is limited research available about this 
and the NIH Consensus statement observes that sexually active couple should avoid pregnancy if 
they are on HU. 
2.6 CONCERNS WITH NON ADHRENCE 
Although Hydroxyurea has been established as an important therapeutic option, research shows 
that HU is underutilized in patients with SCD.  
Patel et al. (2010) determined that in a cohort of children with SCD on HU, patients were 
only partially adherent to HU based on their medication refill records and therefore did not 
receive the full benefits of the medication. 4 Another research study reported 4% non-adherence 
in 17 patients who were started on HU. In two large clinical trials, it was observed that 10% to 
20% of children stopped taking HU due to non-adherence.  
Some issues about the use of HU include concerns about overall safety and effectiveness 
of drug. Researchers have found that 70% of patients who were candidates for HU were either 
not prescribed the medication or were not taking the medication. 5 
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2.6.1 Effect of poor adherence 
Pharmacotherapy can have a range of benefits including symptom reduction, preservation of 
physical function and improving quality of life. However the effectiveness of any medication 
depends on the patient’s adherence to the treatment regimen. Poor adherence can limit the 
benefits of treatment, leading to decreased efficacy, greater adverse effects potential, disease 
relapse, increased medical expenditure and decreased quality of life. 18 
Poor adherence can contribute to substantial worsening of disease and increased 
healthcare costs. Due to this, it is essential to identify specific patients who are at increased risk 
for non-adherence. 4 
2.7 BARRIERS TO ADHERENCE 
Barriers to HU treatment can arise at 4 levels – patient, provider, caregiver and system. The NIH 
consensus states that there have been no interventions performed to address such barriers. 1 The 
most common provider reported barrier is compliance. A survey of pediatric hematologists 
identified that medication compliance, laboratory monitoring compliance and contraception 
compliance as major barriers from the physician. 8 Providers reported that the most common 
reasons for patient’s refusal of HU included fear of cancer and other side effects, not wanting to 
take medication, not wanting lab monitoring and patient’s perception that the drug would not 
work. 10  
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3.0  SPECIFIC AIMS 
This study has three specific aims: 
1. To determine patient reported barriers to adherence of hydroxyurea for individuals with 
Sickle Cell Disease 
2. To determine the patient reported treatment satisfaction of hydroxyurea therapy in Sickle 
Cell Disease 
3. To determine any correlation between patient-reported barriers to Hydroxyurea and 







4.0  STUDY DESIGN AND METHODS 
4.1 PROJECT DEVELOPMENT 
This project was conducted in collaboration with the “Patient Centered Comprehensive 
Medication Adherence Management System to Improve Effectiveness of Disease Modifying 
Therapy with Hydroxyurea in Patients with Sickle Cell Disease” Study (also called Mobile DOT 
study). The Mobile DOT Study was funded by the Patient Centered Outcome Research Institute 
(PCORI) and is a two year research study that aims to improve adherence to Hydroxyurea in the 
Sickle Cell population using individualized structured interventions. This study was approved by 
the University of Pittsburgh IRB and began recruiting participants in February 2014. It is being 
conducted in three different sites – University of Pittsburgh Medical Center Hospitals, Children’s 
Healthcare of Atlanta and Children’s National Medical Center. The Mobile DOT study was 
reviewed and approved by the Institutional Review Boards of all three Universities (Please refer 
Appendix A for IRB approval). 
This project was designed as a sub-study to analyze the patient reported barriers to 
adherence and treatment satisfaction of hydroxyurea. The surveys used in this project were 




4.2 PARTICIPANT POPULATION 
4.2.1 Description of study population 
The participants for this study were recruited from pediatric and adult sickle cell patients who 
received care from the sickle cell programs at the University of Pittsburgh Medical Center 
Hospitals, Children’s National Medical Center and Children’s Healthcare of Atlanta. The 
participant population consists of male and female patients who were evaluated at one of the 
above clinics to determine eligibility as compared to the inclusion/ exclusion criteria. Patients 
with SCD were eligible if they have Hemoglobin SS, SC, SßD, Sß0, Sß0-Arab or Sß+ disease, were 
greater than two years of age, had been prescribed Hydroxyurea for greater than six months and 
were willing and able to participate in the intervention for the Mobile DOT study. Unwillingness 
to participate in the intervention for the Mobile DOT study was a criterion for exclusion from 
this study.  
4.2.2 Patient recruitment  
The multidisciplinary care team at the sickle cell clinics assisted in identifying individuals 
currently on Hydroxyurea for at least six months as prospective subjects for the study.  The 
prospective adult participants and the parent/legal guardian of the pediatric participants were 
mailed a notification of the study. They were also approached directly at clinical appointments 
about the study by either the investigators or research staff. Prospective participants and their 
parent/legal guardian as applicable received an explanation of the study, were offer the 
opportunity to enroll in the study.  
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A member of the research team provided an introduction/ review of the research study, 
including potential risks and benefits, protocol procedures and research team expectations. 
Patients and/or parent/legal guardian were encouraged to ask questions. All prospective 
participants were informed about the voluntary nature of the study and that they can withdraw 
from the study at any time. Consent was obtained from participants 18 years or older, and from a 
parent/legal guardian for participants under 18 years of age. Assent was obtained from all minors 
whenever possible. A copy of the signed consent was offered to all participants, as well as 
parent/ legal guardian as applicable. 
4.3 SURVEYS 
Patients who consented to be a part of the study received the following surveys during a 
scheduled clinical visit.  
4.3.1 Adherence Starts with Knowledge (ASK-12) Survey  
The ASK-12 Survey can be used to measure adherence behavior and barriers to treatment 
adherence. It is a survey designed to measure and determine the barriers to adherence of a 
particular medication. The ASK-12 survey is a validated patient-reported measure of barriers to 
medication adherence and adherence-related behavior. It is a generic instrument applicable to 
patients regardless of their medical conditions.19 It has also been described as a condensed tool 
that offers quick identification of patient specific barriers. The ASK-12 survey was developed by 
GlaxoSmithKline in July 2008 and was reported to demonstrate “adequate reliability and 
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validity”.18 Previous studies have determined that ASK-12 is a reliable and valid questionnaire 
for assessing patient perceptions of potential barriers to medication adherence and adherence 
related behavior. The questions in this survey are designed to address 3 domains or subscales, 
namely, inconvenience/forgetfulness (3 items), health beliefs (4 items) and behavior (5 items). 
(See Appendix B for survey questions). The ASK-12 Survey contains twelve questions and each 
question is scored on a Likert scale ranging from 1 to 5 for each question. The total scores can  
range from 12 to 60 with a higher score representing greater barriers to adherence.18 
4.3.2 Additional barriers survey  
The additional barriers survey was designed to address the barriers specific to hydroxyurea in the 
SCD population. This survey was created by the research team at the Children’s Hospital of 
Pittsburgh of UPMC in February 2014 to better understand and characterize the hydroxyurea 
specific barriers previously reported in this patient population. The ASK-12 survey is a validated 
tool to look at adherence barriers to any medication while the additional barriers survey was 
designed to address barriers that are not present in the former survey. This survey contains ten 
questions that focus on issues specific to hydroxyurea that were determined after reviewing the 
literature. (See Appendix B for survey questions). This survey tool was created as part of the 
Mobile DOT study and has not been used before and is not a validated tool.   
The survey questions are unique to different aspects influenced by Hydroxyurea 
consumption and are analyzed individually. Answers to each question were scored from 1 to 5 
based on a 5-point Likert scale similar to the ASK-12 Survey (“Strongly agree”, “Agree”, 
“Neutral”, “Disagree” and “Strongly Disagree”).    
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4.3.3 Treatment Satisfaction of Medication Adherence (TSQM-9)  
The TSQM survey was designed to evaluate and compare patients’ satisfaction with a given 
medication.20 Previous studies with this survey use it to compare medication adherence and 
treatment satisfaction. In this study, we use the TSQM-9 to measure the participant’s satisfaction 
with hydroxyurea. This questionnaire was created by Quintiles in 2004 and modified to the 
current version in 2009. Several versions of the TSQM surveys have been validated and the 
TSQM-9 was reported as a validated measure in the article “Validation of an abbreviated 
Treatment Satisfaction Questionnaire for Medication (TSQM-9) among patients on 
antihypertensive medication” in April 2009. The survey is described as “a reliable and valid 
measure to assess treatment satisfaction in naturalistic study designs”.20 It has been reported that 
patient satisfaction with their medication is shown to affect treatment-related behavior such as 
likelihood to continue using medication, use medication correctly and adherence to medication 
regimens.21  The questions in the TSQM survey are designed to address 3 domains or subscales – 
Effectiveness (3 items), Convenience (3 items) and Global Satisfaction (3 items). (See Appendix 
B for survey questions). Each question is scored on a scale of 1 to 5 or on a scale of 1 to 7 using 
a Likert scale system. The questions are grouped into domains and each domain is scored on a 
scale of 0 to 100 with higher score indicating higher satisfaction.15  
4.3.4 Survey types 
Each of the above surveys were designed to be administered to adults and pediatric participants. 
The survey was adapted to be eligible to be administered to caregivers of pediatric participants. 
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4.4 DATA COLLECTION AND ANALYSIS 
4.4.1 Data handling and storage 
The surveys were administered as paper questionnaires to the participants during their regular 
clinical visits at each of the three sites. The completed surveys were uploaded onto a secure 
online server by a member of the research team. This server was developed and maintained by 
Data Warehouse Consultants.  
The survey data was extracted from the online secure database on May 15th 2015 as an 
excel file. The data was exported to Minitab® 16 statistical software for analyses.  
4.4.2 Data cleaning and scoring 
The responses to all surveys were coded using the data coding function in the Minitab® 16 
software. The ASK-12 and TSQM-9 surveys were coded as described in the literature.15; 18; 20; 22; 
23 The additional barriers survey were created mirroring the style of the ASK-12 survey. Thus 
data coding and analysis of this survey was performed similar to the ASK-12 data.  
The responses to the ASK-12 survey and additional barriers survey were coded on a 
Likert scale from 1 to 5 with a higher score indicating higher barriers (Appendix B). Raw scores 
were used for questions numbered 1 to 3 and 8 to 12. Reverse scores were used for questions 
numbered 4 to 7 in the ASK-12 Survey. Raw scores were used for questions numbered 13 to 16 
and 18 to 22 in the additional barriers survey. The reverse score was used for question number 17 
in the additional barriers survey.  
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The responses to the TSQM-9 survey were coded on a Likert scale with a higher score 
indicating higher satisfaction with hydroxyurea. Questions numbered 1 to 6 and question number 
9 were coded on a scale of 1-7. Questions numbered 7 and 8 were coded on a scale of 1 to 5. 
Raw scores were used for all TSQM-9 survey responses.  
Surveys completed by two participants from Children’s Healthcare of Atlanta and one 
participant from Children’s National Medical Center were disregarded as each participant 
attempted only one of the above two surveys.  
4.4.3 Analytical methods for specific aim 1 
Table 1. Categorical Classification of the ASK-12 survey 
 ASK-12 Survey questions Category 
1 I just forget to take my medicines some of the time 
Inconvenience/Forgetfulness 2 I run out of my medicine because I don’t get refills on time 
3 Taking medicines more than once a day is inconvenient 
4 I feel confident that each one of my medicines will help me 
Treatment beliefs 
5 I know if I’m reaching my health goals 
6 I have someone I can call with questions about my medicines 
7 My doctor/nurse and I work together to make decisions 
8 Have you taken a medicine more or less often than prescribed? 
Behavior 
9 Have you skipped or stopped taking a medicine because you 
didn’t think it was working? 
10 Have you skipped or stopped taking a medicine because it made 
you feel bad? 
11 Have you skipped, stopped, not refilled, or taken less medicine 
because of the cost? 
12 Have you not had medicine with you when it was time to take it? 
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The ASK-12 survey and additional barriers survey were analyzed separately. The ASK-
12 survey questions were divided into 3 main categories – inconvenience/forgetfulness, health 
beliefs and behavior based on instructions from validated literature.18; 23 Table 1 displays the 
categorical classification of the ASK-12 questionnaire.  
The additional barriers survey were divided into 4 categories – side effects, difficulty, 
transportation and follow up. Table 2 displays the categorical classification of additional barriers 
questionnaire. 
Table 2. Categorical Classification of Additional Barriers Survey 
 Additional Barriers Survey Questions Category 
1 I do not like taking Hydroxyurea because I have to get 
monthly blood draws 
Side effects 
2 It is hard for me to get to monthly clinical visits because of 
my schedule 
Difficulty 
3 It is hard for me to get refills of Hydroxyurea from the 
pharmacy on time 
Difficulty 
4 I am afraid Hydroxyurea will cause me to gain weight or 
lose my hair 
Side effects 
5 There is a someone  who keeps track of my Hydroxyurea 
schedule 
Follow up 
6 It is difficult to take hydroxyurea at a regular time because 
of my work or school  schedule 
Difficulty 
7 It is difficult to get time off from work or school to attend 
doctor’s appointments 
Difficulty 
8 I cannot arrange transportation to go to clinic visits Transportation 
9 I do not like to take Hydroxyurea because I am worried 
about how it will affect my fertility 
Side effects 
10 I do not like to take Hydroxyurea because I am worried 
about how it will affect me in the long term. 
Side effects 
 
Graphical representation of ASK-12 survey subsets and individual additional barriers 
questions was performed to visually represent the survey responses. Interpretation of graphical 
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data was performed whenever possible.  Multiple regression analyses was performed with site of 
survey administration and participant type as predictors. This was used to check for significant 
differences in all subsets of ASK-12 and additional barriers survey based on location of survey 
administration or type of survey participant (Adult, caregiver or pediatric participant). The above 
analyses was performed with a critical level of significance of P<0.05 for each survey. General 
descriptive statistics such as mean, standard deviation and median were determined for each 
survey subset. 
4.4.4 Analytical methods for specific aim 2 
The TSQM-9 survey questions were divided into 3 main subsets – effectiveness, convenience 
and global satisfaction based on instructions from previous literature.15; 20; 22 Table 3 displays the 
categorical classification of TSQM-9 questionnaire.  
Graphical representation of TSQM-9 survey responses was constructed for each survey 
subset to visually represent survey responses. Multiple regression analyses was performed with 
site of survey administration and participant type as predictors. The above analyses was 
performed to check for significant differences in the subsets of TSQM-9 survey based on the 
location of survey administration and the type of participant (adult, caregiver or pediatric) 
responding to the surveys. Analyses were performed with a critical level of significance of 
P<0.05. General descriptive statistics such as the mean, standard deviation and median was 





Table 3. Categorical Classification of TSQM-9 Survey 
 TSQM-9 Survey questions Category 
1 How satisfied or dissatisfied are you with the ability of the 
medication to prevent or treat your condition?  
Effectiveness 
2 How satisfied or dissatisfied are you with the way the 
medication relieves your symptoms? 
3 How satisfied or dissatisfied are you with the amount of 
time it takes the medication to start working? 
4 How easy or difficult is it to use the medication in its 
current form?  
Convenience 
5 How easy or difficult is it to plan when you will use the 
medication each time? 
6 How convenient or inconvenient is it to take the medication 
as instructed? 
7 Overall, how confident are you that taking this medication 
is a good thing for you?  
Global Satisfaction 
8 How certain are you that the good things about your 
medication outweigh the bad things?  
9 Taking all things into account, how satisfied or dissatisfied 
are you with this medication? 
4.4.5 Analytical methods for specific aim 3 
Correlation was determined between each subset of the barrier surveys (ASK-12 and Additional 
Barriers Survey) and each subset of the treatment satisfaction survey (TSQM-9). The Pearson 
moment correlation coefficients were determined along with their P-value to check for linear 
relationships between the above two variables. Scatterplots with regression lines were graphed to 
determine the magnitude of the association and effect of each participant type. Data from subsets 
that displayed significant difference between participating sites were adjusted for by calculating 
partial correlation.  
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5.0  RESULTS 
5.1 DEMOGRAPHICS 
A total of 152 participants took part in this study. Three participants did not attempt both surveys 
and were removed from the analysis. Responses from the remaining 149 participants were used 
in the analyses and interpretation of survey data. The Children’s National Medical Center in 
Washington obtained surveys only from adults and did not have any pediatric or caregiver 
participants. The University of Pittsburgh Medical Centers and the Children’s HealthCare of 
Atlanta had all three types of participants.  
 
Table 4. Enrollment Data and Demographics 
 
















1 21 12 15 48 (32.2 %) 
Children’s Healthcare 
of Atlanta 




3 19 - - 19 (12.7 %) 
TOTAL N 
(%) 
 46 (30.8 %) 48 (32.2 %) 55 (36.9 %) 149 
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Table 4 displays the classification of participants based on location of survey 
administration and type of participant. Out of the 149 total participants, 48 (32.21%) completed 
the surveys at the University of Pittsburgh Medical Centers and 82 (55.03%) took the survey at 
Children’s Healthcare of Atlanta. Of all participating individuals, 48 (32.87%) were minors (<17 
years of age) at the time of survey administration. 55 participants (36.91%) were caregiver 
participants of minors with SCD. The caregiver participant data and pediatric participant data 
were not paired in this study.  
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5.2 BARRIERS TO ADHERENCE 


























































Bar chart - ASK-12 Inconvenience by participant type
ASK-12 Inconvenience subscale value
Figure 1. Bar chart - ASK-12 Inconvenience 
Figure 1 displays the number of individuals who responded to each value of the ASK-12 
inconvenience subset. An ASK-12 subset value >12 represents a high barrier score. 11 
individuals scored >12 for this subscale which indicates that around 7% of the study population 
considered issues related to inconvenience a barrier to consumption of hydroxyurea. Out of the 























































Bar chart - ASK-12 treatment beliefs by participant type
ASK-12 treatment beliefs subscale value 
 
Figure 2. Bar chart - ASK-12 treatment beliefs  
 
Figure 2 displays the number of individuals who responded to each value of the ASK-12 
treatment beliefs subscale. An ASK-12 treatment beliefs value of >16 represents a high barrier 
score. Only 1 pediatric response had a score of >16 for this subscale which indicates that less 
than 1% of the study population considers issues related to treatment beliefs a barrier to 
























































Bar chart - ASK-12 behavior
ASK-12 behavior subscale value  
Figure 3. Bar chart - ASK-12 behavior 
 
Figure 3 displays the number of individuals who responded to each value of the ASK-12 
behavior subscale. An ASK-12 behavior subscale value of >20 represents a high barrier score. 3 
individuals scored >20 for this subscale which indicates that around 2% of the study population 
considers issues related to behavior to be a barrier to consumption of Hydroxyurea. Out of the 3 
individuals 1 is a caregiver response and 2 are pediatric responses. 
The number of individuals experiencing barriers to adherence of HU appears to be low in 




































Additional barriers side effects subscale - Monthly blood draw







































Additional barriers side effects subscale - gain weight and lose hair




































Additional barriers side effects subscale - effect on fertility




































Additional barriers side effects subscale - Long term effects
Response scale   





































Additional barriers difficulty subscale - HU intake hard due to schedule




































Additional barriers difficulty subscale - Time off to attend appointments






































Additional barriers difficulty subscale - Hard to get refills




































Additional barriers difficulty subscale - Monthly visits
Response scale  








































Additional barriers follow up subscale - Someone keeps track of HU
Response scale   
 






































Additional barriers transportation subscale - Cannot arrange transport
Response scale  
 
Figure 7. Additional Barriers Survey transportation subscale response 
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Figures 4, 5, 6 and 7 are graphical representations of responses to the additional barriers survey 
questions in this study population. Table 5 shows the number of individuals who scored >4 for 
each question. The observation of above data shows that an increased number of individuals 
have reported higher level of barriers for questions of this survey compared to the ASK-12 
survey.  
Table 5 indicates two questions in the additional barriers survey show a larger number of 
individuals reporting increased level of barriers. The statement “There is a someone who keeps 
track of my hydroxyurea schedule” was reported as a high level of barrier by 47 individuals 
(33%). This finding is difficult to interpret in adults with SCD due to the phrasing of question, 
which may have confused adult participants. However, in the pediatric and caregiver 
populations, it is possible that this question is still applicable because most pediatric patients 
have a caregiver to assist them with medication management and refills. Therefore, this may 
represent a true barrier in these two groups.    
“It is difficult to take HU at a regular time because of my work or school schedule” is 
another question that 23 individuals (15%) reported as a high level of barrier. This could indicate 
that scheduling a specific time for HU intake may be a challenge for individuals. “I cannot 
arrange transportation to go to clinic visits” yielded a much lower number of individuals 







Table 5. Number of responses - Additional barriers survey 
 Additional Barriers Survey Questions N 
1 I do not like taking Hydroxyurea because I have to get 
monthly blood draws 
11 
2 It is hard for me to get to monthly clinical visits because of 
my schedule 
13 
3 It is hard for me to get refills of Hydroxyurea from the 
pharmacy on time 
8 
4 I am afraid Hydroxyurea will cause me to gain weight or 
lose my hair 
16 
5 There is a someone  who keeps track of my Hydroxyurea 
schedule 
47 
6 It is difficult to take hydroxyurea at a regular time because 
of my work or school  schedule 
23 
7 It is difficult to get time off from work or school to attend 
doctor’s appointments 
14 
8 I cannot arrange transportation to go to clinic visits 4 
9 I do not like to take Hydroxyurea because I am worried 
about how it will affect my fertility 
8 
10 I do not like to take Hydroxyurea because I am worried 




5.2.2 Regression analysis 
A multiple regression analysis was performed to investigate the relationship between the survey 
responses and its association with two predictors – site of survey administration and participant 
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type. The model compared survey responses to each predictor independent of the other predictor. 
The least squares estimation fit regression model was used to perform a multiple regression 
analysis with each survey subset as the continuous response variable and survey site and 
participant type as categorical predictor variables. Significance is determined by establishing 
P<0.05 for entire survey which would translate into P<0.013 for each survey subset to counteract 
multiple comparisons using Bonferroni correction. 
In the tables describing the results of the regression analyses, Coef refers to the beta 
coefficient of the analysis (change in the response variable caused by a unit change in the 
predictor variable), SEcoeff refers to the standard error of this coefficient and the T value refers 
to the test statistic. 
The P-value for estimated coefficients between all three sites is greater than the 
established α level of 0.013 for the ASK-12 survey subsets and the additional barriers survey 
subsets. We observed no significant difference between the survey responses based on the 
location of survey administration for any subset of ASK-12 and additional barriers surveys. 
 
Table 6. Results of Simple Regression for ASK-12 Survey and Participant type 
ASK-12 Inconvenience 
Term Coef SEcoef T value P-value 
Adult and Caregiver -2.349 0.690 -0.3.41 0.001* 
Pediatric and Caregiver 2.129 0.538 3.96 0.000* 
Adult and Pediatric -0.220 0.708 -0.31 0.756 
ASK-12 Treatment Beliefs 
Term Coef SEcoef T value P-value 
Adult and Caregiver -0.920 0.673 -0.37 0.174 
Pediatric and Caregiver 1.415 0.524 2.7 0.008* 
Adult and Pediatric 0.495 0.698 0.71 0.4791 
ASK-12 Behavior 
Term Coef SEcoef T value P-value 
Adult and Caregiver -2.122 0.878 -2.42 0.017 
Pediatric and Caregiver 1.884 0.674 2.79 0.006* 
Adult and Pediatric -0.238 0.896 -0.27 0.790 
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Table 6 displays the results of regression analyses between each subset of the ASK-12 
survey and type of participant attempting the survey. The P-values for estimated coefficients 
between adult and pediatric participants are greater than the established α level of 0.013 for all 
three categories. This implies there is no significant relationship between adult and pediatric 
participant’s response to all three ASK-12 categories.  
The P-value for the coefficients between the pediatric and caregiver participants are 
consistently less than 0.013 for each subset. We conclude from this information that there is a 
difference between the ASK-12 survey responses by the caregivers and the pediatric participants 
to all three survey categories. This finding could indicate that caregivers’ understanding of 
barriers experienced by the pediatric population could be different. This finding could also be a 
representation of a difference in barriers expressed by adolescents who independently consume 
medication and their caregivers’ understanding of these barriers.  
When examining the relationship between adults and caregivers based on survey 
response, we see that the P-value of the coefficient in the inconvenience subset is 0.001. This 
result suggests a difference in response between adults and caregivers in the inconvenience 
category of the ASK-12 survey. No significant relationship was seen between adults and 
caregivers in the treatment beliefs and behavior categories of the ASK-12 survey. 
To summarize, there appears to be an association between the participant type and certain 






Table 7. Results of Regression for Additional Barriers Survey and Participant Type 
HU Side Effects 
Term Coef SEcoef T value P-value 
Adult and Caregiver -0.123 0.783 -0.16 0.876 
Pediatric and Caregiver 0.081 0.613 0.13 0.894 
Adult and Pediatric -0.041 0.806 -0.05 0.959 
HU Difficulty 
Term Coef SEcoef T value P-value 
Adult and Caregiver -1.302 0.709 -1.84 0.069 
Pediatric and Caregiver 0.599 0.551 1.09 0.279 
Adult and Pediatric -0.703 0.727 -0.97 0.335 
HU Transportation 
Term Coef SEcoef T value P-value 
Adult and Caregiver -0.279 0.195 -1.43 0.154 
Pediatric and Caregiver -0.027 0.151 -0.18 0.858 
Adult and Pediatric -0.306 0.200 -1.53 0.128 
HU Follow Up 
Term Coef SEcoef T value P-value 
Adult and Caregiver -0.942 0.367 -2.57 0.011** 
Pediatric and Caregiver -0.355 0.285 -1.25 0.215 
Adult and Pediatric -1.297 0.376 -3.45 0.001** 
 
Table 7 describes the result of the regression analysis between the additional barriers 
survey subsets and the type of participant who attempted the survey. The P-value for estimated 
coefficients were all greater than the established α level of 0.013 for three subsets - HU Side 
effects, HU difficulty and HU transportation. The above three categories of the Additional 
Barriers Survey show no significant relationship with participant type.  
The P-value of the coefficient between adult and caregiver responses in the HU follow up 
subset showed significance at 0.011 indicating presence of a difference in response between 
adults and caregivers to this category of the survey. Additionally, the relationship between 
participant type and, pediatric and adult responses showed significance with a P-value of 0.001. 
This indicates the presence of a difference between adult and pediatric responses to the follow up 
subset of the Additional barriers survey.  
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5.2.3 Descriptive statistics 
Table 8 and Table 9 display the descriptive statistics of the ASK-12 survey and additional 
barriers survey respectively. The tables show the number of individuals who responded to each 
survey subset (N), number of missing responses (N*), mean, standard deviation and median by 
participant type. The last two columns of the table reports the results of a one sample two 
tailed T-test to check for significant difference from the neutral response for each subset of the 
barriers survey. The T-value represents the size of the difference with respect to variation in the 
response means. The greater the T-value the more evidence against the hypothesis that the 
population mean is equal to the neutral value. 
Table 8. Descriptive statistics of ASK-12 Survey 
Variable               Participant Type    N N* Mean StDev Median T-value P-value 
ASK-12 Inconvenience 
(3 items with a neutral score 
of 9) 
Adult 46 0 8.457 2.44 8.00 -1.51 0.138 
Caregiver 53 2 6.057 2.685 6.00 -7.98 0.000 
Pediatric 47 1 8.191 2.856 8.00 -1.94 0.058 
ASK-12 Treatment Beliefs 
(4 items with a neutral score 
of 12) 
Adult 46 0 7.304  2.010    7.500   -15.85 0.000 
Caregiver 55 0 6.255  2.743    5.000   -15.61 0.000 
Pediatric 46 2 7.696  3.054    7.500   -18.45 0.000 
ASK-12 Behavior 
(5 items with a neutral score 
of 15) 
Adult 46 0 9.500  2.904 10.00   -12.86 0.000 
Caregiver 54 1 6.815  3.263    5.000   -11.69 0.000 
Pediatric 48 0 8.688 3.974    8.000   -11.00 0.000 
ASK-12 Total 
(12 items with a neutral 
score of 36) 
Adult 46 0 25.261 5.268 25.000 -13.85 0.000 
Caregiver 52 3 19.038 6.039 18.500 -20.25 0.000 
Pediatric 45 3 24.71 7.65 24.0 -9.90 0.000 
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In Table 8, the mean and median of the caregiver response to all three categories of the 
ASK-12 survey is lower in comparison to that of adult and pediatric participants. This could 
indicate lower barriers with respect to all categories indicated by the caregiver participants. The 
inconvenience subset shows that the responses of the adult and pediatric participants are not 
significantly different from neutral response but the caregiver response is significantly different 
from the neutral value.  
The negative T value indicates that the mean of the subscales are lower than the neutral 
value. It can be observed from the T-value of each subset that the treatment beliefs subscale has 
the most significant difference from the neutral response followed by the behavior subset and 
lastly by the inconvenience subscale.  
 The total ASK-12 responses can be scored from 12 to 60 for all participants. The ASK-
12 total response for adults, caregivers and pediatric participants are 25.261, 19.038 and 24.71 
which indicates a low threshold of barriers.  
Table 9. Descriptive statistics of Additional Barriers Survey 
Variable                Participant Type    N N* Mean StDev Median T-value P-value 
HU Side Effects 
(4 items with a 
neutral score of 12) 
Adult 45 1 7.733 2.895 7.000 -9.89 0.000 
Caregiver 54 1 7.167 3.161 7.000 -11.24 0.000 
Pediatric 46 2 7.239 3.042 7.000 -10.61 0.000 
HU Difficulty 
(4 items with a 
neutral score of 12) 
Adult 46 0 8.109   2.885     8.500    -9.15 0.000 
Caregiver 53 2 7.132   2.602 7.000 -13.62 0.000 
Pediatric 48 0 7.750 2.787 8.000 -10.57 0.000 
HU Follow Up 
(1 item with a neutral 
score of 3) 
Adult 46 0 3.196   1.470 3.000 0.90 0.371 
Caregiver 53 2 2.566 1.421 2.000 -2.22 0.031 
Pediatric 48 0 2.208 1.429 2.000 -3.84 0.000 
HU Transportation 
(1 item with a neutral 
score of 3) 
Adult 46 0 1.696   0.695 2.000 -12.73 0.000 
Caregiver 53 2 1.547 0.845 1.000 -12.52 0.000 
Pediatric 48 0 1.521 0.714 1.000 -14.35 0.000 
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Table 9 shows the mean and median values for the different types of participants in all 
subsets of the additional barriers survey. The value of the T-tests shows significant difference 
from the neutral value for three of the four survey subsets. Transportation subset showed the 
most significant difference from the neutral value while the side effects and difficulty subscales 
appeared to have similar significant differences from the neutral value. The adult and the 
caregiver responses appear to have no significant difference from the neutral value for the follow 
up category indicating that the responses by the adult and caregivers were not significantly 
different from a neutral response.  
The negative T-value indicates that the mean of the subscales are lower than the neutral 
values. The pediatric participant subset showed presence of a significant difference but the T 
value is much lower than the other subsets indicating lesser deviation of the mean from the 
neutral response. 
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5.3 TREATMENT SATISFACTION 

























































Bar chart - TSQM-9 survey- Effectiveness subset by participant type
TSQM-9 Effectiveness score in Percentage  
Figure 8. Bar chart - TSQM-9 effectiveness subset 
 
Figure 8 displays the distribution of responses to the TSQM-9 survey effectiveness 
subscale based on participant type. The TSQM-9 subscale values are converted into a numeric 
response between 0 and 100. 13% of adults, 29% of caregivers and 22% of pediatric participants 
have reported a score >87 for the effectiveness subscale. This indicates that a larger percent of 
caregiver participants experienced a higher level of satisfaction compared to pediatric and adult 




























































Bar chart - TSQM-9 Convenience subset by participant type
TSQM-9 Convenience score in percentage  
 
Figure 9. Bar chart - TSQM-9 Convenience subset 
 
Figure 9 shows the distribution of the adult, pediatric and caregiver responses to the 
TSQM-9 convenience subset. 28% of adults, 38% of caregivers and 27% of pediatric participants 
report a score >87 for this subset. This subset also displays a larger percentage of caregiver 
























































Bar chart - TSQM-9 Global Satisfaction subset by participant type 
TSQM-9 Global satisfaction score in percentage  
 
Figure 10. Bar chart - TSQM-9 Global satisfaction 
 
Figure 10 represents the distribution of the TSQM-9 survey responses in the global 
satisfaction subsets based on participant type. 32% of adult participants 42% of pediatric 
participants and 42% of caregiver participants provided a response >87 for this category of the 
TSQM-9 survey. This subset indicates a smaller percent of adults experiencing high treatment 




5.3.2 Regression analysis  
A multiple regression analysis was performed to investigate the relationship between the TSQM-
9 survey responses and its association with two predictors – Site of survey administration and 
participant type.  
The results of regression analysis for the subsets of the TSQM-9 survey with participant 
type shows no significant difference for any of the three subsets. P-values for estimated 
coefficients of all types of participants were greater than the established α level of 0.013. This 
implies that all the TSQM-9 survey subsets show no significant relationship with adult, caregiver 
or pediatric participants. 
Table 10. Results of Regression for TSQM-9 Survey and Participant Sites 
TSQM-9 Effectiveness 
Term Coef SEcoef T value P-value 
Site 1 and 3 -0.0840 0.0445 -1.89 0.061 
Site 1 and 4 0.0107 0.0295 0.36 0.717 
Site 3 and 4 0.0947 0.0496 1.91 0.058 
TSQM-9 Convenience 
Term Coef SEcoef T value P-value 
Site 1 and 3 -0.0751 0.0474 -1.58 0.116 
Site 1 and 4 0.0033 0.0315 0.11 0.916 
Site 3 and 4 0.0784 0.0529 -1.48 0.141 
TSQM-9 Global Satisfaction 
Term Coef SEcoef T value P-value 
Site 1 and 3 -0.1270 0.0461 -2.75 0.007** 
Site 1 and 4 0.0304 0.0311 0.98 0.330 
Site 3 and 4 0.1573 0.0516 3.05 0.003** 
 
Table 10 shows the results of regression analysis for the subsets of the TSQM-9 survey 
with participant site. P-value for estimated coefficients of all participant sites are greater than the 
established α level of 0.013 for the effectiveness and convenience subsets of this survey. This 
implies that the two subsets show no significant relationship with participant site.  
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The P-value of the coefficient between site 1 and 3 for the responses of the global 
satisfaction shows significance at P=0.007 indicating the presence of a significant difference in 
response between Site 1 and Site 3 for this part of the survey. Also, the P-value of Site 3 and 4 
show a significant relationship at 0.003. Thus there is a significant difference in responses 
between site 3 and 4 as well. The significant difference between site responses could be 
explained by the type of participants in each of the sites. Site 3 enrolled only adult participants 
while sites 1 and 4 enrolled pediatric, adult and caregiver participants.  
5.3.3 Descriptive statistics 
Table 11. Descriptive statistics for TSQM-9 survey subsets 
 
Table 11 show the number of individuals who responded to each survey subset (N), number of 
missing responses (N*), mean, standard deviation and median by participant type. The last two 
columns of the table reports the results of a one sample two tailed T-test to check for significant 
difference from the central value for each subset of the TSQM-9.  
Variable                Participant Type    N N* Mean StDev Median T-value P-value 
TSQM-9 Effectiveness 
(3 items with a central value 
of 57.14) 
Adult 45 1 70.26 13.96 71.43 6.30 0.000 
Caregiver 55 0 78.26 15.14 76.19 10.35 0.000 
Pediatric 48 0 77.38 14.45 76.19 9.70 0.000 
TSQM-9 Convenience 
(3 items with a central value 
of 57.14) 
Adult 45 1 77.04 16.13 80.95 8.28 0.000 
Caregiver 55 0 82.25 15.21 85.71 12.24 0.000 
Pediatric 46 2 81.16 15.06 83.33 10.82 0.000 
TSQM-9 Global Satisfaction 
(3 items with a central value 
of 58.82) 
Adult 46 0 75.96 16.02 76.47 7.97 0.000 
Caregiver 55 0 83.10 14.46 82.35 13.31 0.000 
Pediatric 47 1 81.60 16.53 82.35 10.14 0.000 
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The T-test shows all T-values to be positive with significant difference from the central 
value. The positive nature of the T-values implies the sample means for all subsets are greater 
than the central value. Thus all participants show significantly high treatment satisfaction for all 
categories.   
The mean for the effectiveness subset of the treatment satisfaction survey is lower for the 
adults at 70.26 compared to the caregiver and pediatric means of 78.26 and 77.38. Similarly the 
mean for adult participants is lower than the means of the caregiver and pediatric participants for 
Convenience and Global Satisfaction subsets.  This indicates that adults may experience a lower 
level of treatment satisfaction to hydroxyurea compared to the pediatric participants. This is 
supported by the lower T-value of adult survey participants compared to the pediatric and 
caregiver participant types. 
The similar means for all three subsets in pediatric and caregiver category of the surveys 
indicate that caregivers may have an accurate understanding of the treatment satisfaction of the 
minor under their care. 
5.4 CORRELATION BETWEEN BARRIERS AND TREATMENT SATISFACTION 
The third aim of this study is to determine the presence of correlation between the subsets of 
barriers and the subsets of the treatment satisfaction survey. Correlation between data is obtained 
by determining the Pearson Correlation Coefficient. Partial correlation analyses were performed 




1. ASK-12 categories – partial correlation while adjusting for the effects of participant type 
2. TSQM9 Global Satisfaction – Partial correlation while adjusting for the effects of 
participant sites 
3. Additional Barriers Follow Up – Partial correlation while adjusting for the effects of both 
participant sites and participant type 
5.4.2 Correlation 
The Pearson product moment correlation evaluates the presence of a linear relationship between 
continuous variables. A linear relationship is defined as the association of a change in one 
variable to a proportional change in another variable. 
Table 12 displays the results of the correlation analyses between treatment satisfaction 
and barriers survey responses while adjusting for the appropriate factors. All the correlation 
coefficients obtained are negative (except for the last value that shows no correlation) which 
implies an inverse relationship between the two variables, i.e, as one variable decreases, the other 
variable increases. 
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There is a weak linear relationship observed between all categories of the TSQM-9 
survey and the ASK-12 inconvenience subset. The strongest linear relationship observed is 
between the TSQM-9 convenience and ASK-12 inconvenience subset. This indicates that as the 
barriers in the inconvenience subset decrease, the treatment satisfaction in the convenience 
subscale increases. There is another weak linear relationship observed between all subsets of the 
TSQM-9 survey and the side effects subset of the additional barriers survey. This implies that as 
the side effects are reduced the treatment satisfaction for hydroxyurea increases. The last weak 
linear relationship observed is between the convenience subset of TSQM-9 survey and the 
difficulty subset of the Additional barriers survey. This could imply that as the barriers in the 
difficult subset are reduced, it improves the convenience of medication use.  
5.4.3 Exploring statistical interaction effects 
Scatterplots are statistical tools used to display the association between two variables by plotting 
the values on a graph. The regression line in scatterplots illustrates the relationship between the 
two groups and is graphical representation of the regression equation. A scatterplot with 
regression and groups is used to display the association of two variables and plot regression lines 
based on a specified categorical group. This type of scatterplot was used to examine the potential 
relationship between the barriers subsets and the treatment satisfaction subsets by participant 
type. A scatterplot was created between each barriers subset and each treatment satisfaction 
subset. The plots were grouped based on participant type to check for any difference between the 
association of the two variables for adults, caregivers and pediatric participants. 
Ideally, we expect all regression lines for each graph to have similar slopes and therefore 
indicating equal contribution to the correlation between the two subsets. This analysis was 
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performed check if a particular participant type influenced the correlation more than the other 
two participant types.   
Figure 11, Figure 12 and Figure 13 display the scatterplots between the barriers 
subsets and treatment satisfaction subsets grouped by participant type.  Most of the 
scatterplots display regression lines with similar slopes indicating equal contributions by each 
participant type to the correlation between the two subsets. However a few graphs show a 
difference in slope between participant types which could indicate that one particular group is 
driving the correlation with limited contribution from the other two groups. In the scatterplot 
between the ASK-12 treatment beliefs barriers subset and global satisfaction subset of TSQM-9, 
the regression lines of both the pediatric and adult participants are almost parallel to the X axis 
while the caregiver regression line shows a negative slope. This indicates that any correlation 
seen between these two subsets is driven by the responses of the caregiver participants. The 
same pattern is observed in the scatterplot between the additional barriers difficulty subtype 
and convenience subset of TSQM-9, indicating that any correlation observed between the 
two subsets is driven by the caregiver participant responses. While there was no 
significant correlation observed for the former scatterplot, the latter showed presence of 
weak linear correlation. Further analyses is required to provide more concrete interpretation on 


































































    
 
 


































































































































    
 
   




































































































































    
 
 Figure 12. Scatterplot - ASK-12 vs TSQM-9 
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6.0  DISCUSSION 
Sickle cell disease (SCD) is a genetic disorder that is characterized by pain episodes, acute chest 
syndrome, splenic sequestration, infection, stroke, aplastic crisis, and priapism. While there are 
reports available in the literature on the barriers experienced by this population1; 24; 26, there is 
little research that has examined patient reported treatment satisfaction. This study examined 
patient reported barriers to adherence of hydroxyurea and patient reported treatment satisfaction. 
It also investigated the possible association between barriers and satisfaction. 
The first aim of this study was to determine the barriers to adherence of hydroxyurea in 
individuals with SCD (self-reported and/or parent proxy for minors). Due to an increased number 
of caregiver participants (55) compared to pediatric participants (48), unpaired testing was 
performed for all participant types. However, a large proportion of the data contains paired 
responses between the caregiver and pediatric participants. The significant difference in 
responses of the caregiver and pediatric participants in all three subsets of the ASK-12 survey 
indicates the possibility of a difference in perception of barriers experienced by the pediatric 
individuals by caregiver and pediatric participant groups. Interestingly, lower barrier means were 
found for caregiver participants for all three subsets of the ASK-12 survey when compared to 
pediatric and adult participants. Lack of agreement between pediatric and caregiver participants 
has been previously observed in literature with respect to other medication.27 It may be important 
to consider that caregivers report lower level of barriers because they do not experience the 
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disease themselves.  A study comparing caregiver reported barriers for caregivers who are 
affected with SCD to caregivers who do not have the disease would help determine if caregiver 
bias is a possible cause for this difference. Overall, the number of individuals experiencing 
barriers to adherence of hydroxyurea appears to be low in this population. There is no previous 
literature outlining quantitative analysis of patient reported barriers to adherence of hydroxyurea 
thus limiting the interpretation of this data. 9 
The additional barriers survey follow up subset showed several significant results. The 
significant difference between the adult responses when compared to both pediatric and 
caregiver responses may indicate a difference in perception of medication follow up. This subset 
is limited in its interpretation for adults due to the phrasing of the question which may be 
confusing for adults (Please refer Table 2 for categorical classification of survey). However, a 
high number of caregivers and pediatric participants have also reported this to be a barrier to 
adherence encouraging further research to determine the nature of this barrier. Categorical 
examination of the ASK-12 survey revealed lower levels of barriers than what has previously 
been reported in studies.9 This difference could be due to population bias as we only included 
individuals already on hydroxyurea from tertiary care centers. The responses could also be 
influenced by reporting bias of caregivers and adults who may wish to provide more socially  
acceptable answers.9 15% of individuals reported one question from the difficulty subset - “It is 
difficult to take hydroxyurea at a regular time because of my work or school schedule” – to be a 
barrier. This indicates that scheduling a specific time for hydroxyurea intake may be a challenge 
for individuals.  Less than 2% of individuals have expressed transportation to be a barrier to 
adherence of hydroxyurea. This result is different from the previous qualitative studies that have 
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often described transportation to be a barrier to use of hydroxyurea24; 25. This could indicate the 
presence of patient reporting bias in this population or a population selection bias.  
The second aim of the study was to examine treatment satisfaction with the use of 
hydroxyurea. Analysis revealed that responses to the global satisfaction category of TSQM-9 
survey were influenced by the location of the study participants. This could indicate that 
satisfaction may have a geographical influence with individuals from site 3 having a consistently 
different satisfaction compared to the other two sites. The presence of only adult participants at 
site 3 compared to the three different participant types at the other two sites may also have 
played a role in generating this difference. The mean for all three categories of the treatment 
satisfaction survey is a lower for the adults compared to the caregiver and pediatric means 
indicating that adults may experience a lower level of treatment satisfaction compared to the 
other participant types. However, available literature, though limited, show no such relationship 
existing in previous studies of medication treatment satisfaction.28 The similar means for all three 
categories in pediatric and caregiver category of the surveys indicate that caregivers may have an 
accurate understanding of the treatment satisfaction of the minor under their care. 
The third aim of the study was to examine any correlation that may exist between the data 
from the ASK-12 and additional barriers survey and the treatment satisfaction observed from the 
TSQM-9 survey. All the correlation coefficients obtained were negative implying an inverse 
association between the two variables. The absence of a strong correlation between any of the 
barriers subsets and the treatment satisfaction subset indicates that no single barrier has a strong 
effect on treatment satisfaction. A weak linear relationship was observed between all categories 
of the TSQM-9 survey and the ASK-12 Inconvenience subset as well as the side effects subset of 
the additional barriers survey. This implies that as the side effects and inconvenience barriers are 
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reduced the treatment satisfaction for hydroxyurea increases. This leads to avenues of potential 
research that could address fear of side effects to improve treatment satisfaction to hydroxyurea. 
Another weak linear relationship was observed between the convenience subscale of TSQM-9 
survey and the difficulty subset of the additional barriers survey. This could indicate that as the 
barriers in the difficult subset are reduced, it improves the convenience of medication use. 
However, the scatterplot of the above two subsets show that the correlation is largely driven by 
the caregiver participant population.  
6.1 LIMITATIONS 
The patient population used in this study was selected based on their use of hydroxyurea. 
Therefore, the study sample does not capture the barriers and thoughts of individuals who have 
not been offered this drug, who have declined this drug or who have been on the medication for 
less than 6 months. Subjective measures of adherence like the ASK-12 survey as well as the 
TSQM-9 are subject to potential inaccuracy because they depend on the participant’s memory 
and willingness to report poor adherence or low treatment satisfaction.  
 This study has only examined a linear relationship between the two survey variables. 
However other relationships are possible between these variables. Since the Pearson correlation 
coefficient is very sensitive to extreme values, a single outlier can change the value of the 
correlation coefficient.  
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6.2 FUTURE STUDIES 
This study provides a novel quantitative analysis of barriers to adherence of hydroxyurea and 
treatment satisfaction to this medication. As part of an ongoing study, this data will help analyze 
the barriers expressed by the same population after implementing an intervention for a period of 
time. Exploring specific barriers and their relationship to treatment satisfaction will provide 
valuable information for clinicians and future studies. Educational interventions that address 
individuals’ fear of side effects and difficulty with scheduling medication could potentially 
improve medication adherence.   
A paired analysis of caregiver and pediatric responses could provide more information on 
their perceptions of barriers to medication. This study also brings into question the degree of a 
caregiver’s understanding of barriers faced by children with SCD. Another potential avenue for 
future research would include qualitative and quantitative analysis of caregivers with this 
disorder to explore the ways in which their perceptions may differ from caregivers without SCD.   
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7.0  CONCLUSION 
This is the first study that examines patient reported barriers to hydroxyurea and patient reported 
treatment satisfaction in adults and pediatric individuals with SCD as well as caregivers of 
pediatric individuals with SCD. It offers insight to patients’ understanding of barriers and their 
level of satisfaction with medication adherence. The survey results suggest that two specific 
questions present in the additional barriers surveys may be examined in greater detail to 
understand the role of barriers. Overall, it appears that this study population has low concerns for 
barriers and a moderate to high level of treatment satisfaction. The study also provides 
information on correlation between the barriers and treatment satisfaction survey. A weak 
correlation was found between several subsets of barriers survey and treatment satisfaction 
subsets. Further research could define how interventions to these barriers influence the outcomes 
of adherence to hydroxyurea. 
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C.3 REGRESSION TABLES 
 
Results of Regression for ASK-12 Survey and Participant Sites 
ASK-12 Inconvenience 
Term Coef SEcoef T value P-value 
Site 1 vs 3 0.437 0.813 0.54 0.592 
Site 1 vs 4 0.220 0.544 0.41 0.686 
Site 3 vs 4 -0.216 0.909 -0.24 0.812 
ASK-12 Treatment Beliefs 
Term Coef SEcoef T value P-value 
Site 1 vs 3 1.449 0.794 1.83 0.070 
Site 1 vs 4 0.785 0.535 1.47 0.145 
Site 3 vs 4 -0.664 0.888 -0.75 0.456 
ASK-12 Behavior 
Term Coef SEcoef T value P-value 
Site 1 vs 3 -0.40 1.03 -0.39 0.698 
Site 1 vs 4 -0.193 0.693 -0.72 0.087 
Site 3 vs 4 0.079 1.15 0.69 0.492 
 
Results of Regression for Additional Barriers Survey and Participant Sites 
HU Side Effects 
Term Coef SEcoef T value P-value 
Site 1 vs 3 0.326 0.939 0.35 0.729 
Site 1 vs 4 -0.532 0.619 -0.86 0.391 
Site 3 vs 4 -0.86 1.05 -0.82 0.414 
HU Difficulty 
Term Coef SEcoef T value P-value 
Site 1 vs 3 0.033 0.836 0.04 0.969 
Site 1 vs 4 0.577 0.559 1.03 0.304 
Site 3 vs 4 0.544 0.934 0.58 0.561 
HU Transportation 
Term Coef SEcoef T value P-value 
Site 1 vs 3 -0.283 0.230 -1.23 0.220 
Site 1 vs 4 0.023 0.154 0.15 0.880 
Site 3 vs 4 0.307 0.257 1.19 0.235 
HU Follow Up 
Term Coef SEcoef T value P-value 
Site 1 vs 3 -0.893 0.432 -2.06 0.041 
Site 1 vs 4 -0.096 0.289 -0.33 0.740 
Site 3 vs 4 0.797 0.483 1.65 0.101 
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Results of Regression for TSQM-9 Survey and Participant types 
TSQM-9 Effectiveness 
Term Coef SEcoef T value P-value 
Adult and Caregiver 0.0401 0.0371 -0.108 0.282 
Pediatric and Caregiver 0.0093 0.0286 0.33 0.745 
Adult and Pediatric 0.0093 0.0384 -0.80 0.425 
TSQM-9 Convenience 
Term Coef SEcoef T value P-value 
Adult and Caregiver 0.0201 0.0396 0.51 0.612 
Pediatric and Caregiver 0.0110 0.0308 0.36 0.721 
Adult and Pediatric 0.0091 0.0410 0.22 0.825 
TSQM-9 Global Satisfaction 
Term Coef SEcoef T value P-value 
Adult and Caregiver 0.0009 0.0391 0.02 0.982 
Pediatric and Caregiver 0.0162 0.0303 0.53 0.594 
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